Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2014—AstraZeneca announced it has entered into a collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291, AstraZeneca’s investigational compound in clinical development for non-small cell lung cancer.
October 2014—Enzo Life Sciences now offers the Amp’d GLP-1 ELISA Kit, a rapid ELISA for the detection of the active form of glucagon-like peptide 1. The kit can be used to quantify the active form of human GLP-1 in serum and plasma samples.
October 2014—Viewics released its Utilization Management solution specifically designed for laboratories. The Viewics solution enables laboratories and pathology groups to leverage massive amounts of data into customized dashboards, analyses, and insights that drive successful utilization management initiatives.
October 2014—The Cells-to-CT 1-Step Power SYBR Green Kit from Life Technologies makes it possible to perform expression analysis directly from cultured cells without RNA purification. This new addition includes cell lysis reagents with gDNA removal and the Power SYBR Green 1-Step RT-PCR master mix.
October 2014—The Viaflo Assist is a multichannel pipette from Integra that works with Viaflo II electronic pipettes to prevent users from repetitive strain injuries and to significantly increase the reproducibility of prolonged pipetting protocols such as serial dilutions, plate fillings, and reagent addition.
October 2014—Illumina announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation-sequencing-based oncology test system.
October 2014—The bioT3 Metastatic Cancer Solution from BioTheranostics now includes a single assay that covers genetic mutations and protein expression.
October 2014—The Clinical and Laboratory Standards Institute released a new edition of its document Quality Control of Microbiological Transport Systems; Approved Standard—Second Edition (M40-A2). This document provides criteria to assist manufacturers and end users of transport devices in providing and selecting dependable products for the transport of microbiological clinical specimens.
October 2014—The Clinical and Laboratory Standards Institute released a new microbiology standard, Principles and Procedures for Detection of Anaerobes in Clinical Specimens; Approved Guideline (M56-A).
October 2014—In its 20th catalog edition, Semrock introduces seven groundbreaking LED light engine filter sets. The sets are optimized for compatibility with the most popular LED-based light engines on the market.
